Effect of metformin on food intake in obese subjects

Paolisso, Giuseppe; Amato, Luca; Eccellente, R; Gambardella, A.; Tagliamonte, Maria; Varricchio, G.; Carella, Carlo; Giugliano, Dario; D'Onofrio, F

doi:10.1046/j.1365-2362.1998.00304.x

Cited by 125 publications

(95 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, in our study no significant differences reported in BMI reduction due to dose escalation; this is in agreement with the Cochrane review of insulin sensitizing drugs for polycystic ovary syndrome, which showed no evidence of effect of increasing the dose of metformin on the degree of reduction in BMI [29]. Morin et al have demonstrated that insulin sensitizing therapy with metformin results in a decrease in leptin levels in patients PCOS [30]; meanwhile, Paolisso et al supported the data of Morin et al by showing that metformin decreases leptin in obese non-diabetics [31]. In the present study, serum leptin levels decreased in all patients groups after 3 months of treatment with metformin to levels lower than that reported in healthy controls, and as an exception to all evaluated parameters, the metformin-induced decrease in leptin levels was found to be dose-related, but only correlated with serum metformin due to administration of 2000 mg/day; this finding require further investigations.…”

Section: Discussionsupporting

confidence: 77%

Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

Kadhim¹,

Ismael²,

Khalaf³

et al. 2012

JDM

View full text Add to dashboard Cite

Despite the extensive clinical experience with the use of metformin worldwide, no formal doseranging study has been conducted because the current dosing strategy of metformin was determined empirically, rather than by an understanding of its dose-response relationship in patients with type 2 diabetes. The present study was designed to evaluate the correlation between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes. Sixty type 2 diabetic females were recruited for the study and were allocated into 3 groups; each receiving metformin 1000, 1500 and 2000 mg/day respectively for 3 months. Blood samples withdrawn from each patient at zero time and after 3 months is used to evaluate serum levels of HbA1c, glucose, leptin and insulin, in addition, the measurement of serum level of metformin in blood after 3 months by HPLC. The results demonstrated that all the treated groups with different doses of metformin showed significant improve in all parameters; the use of increased metformin doses was only correlated with plasma leptin levels in the highest dose. In conclusion, serum metformin levels are not good predictors for correlating improvement in clinical and biochemical parameters with increasing the dose in newly diagnosed non-insulin resistant females with type 2 diabetes.

show abstract

Section: Discussionsupporting

confidence: 77%

Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

Kadhim¹,

Ismael²,

Khalaf³

et al. 2012

JDM

View full text Add to dashboard Cite

show abstract

“…At the time before the operation, metformin was the only antidiabetic agent available which was expected to have effect on weight reduction. The evidence for metformin in obesity is insufficient (20), and few studies have reported the effect of metformin on obesity (21,22). In the present case, neither metformin nor fluvoxamine were affective to alter her appetite.…”

Section: Discussioncontrasting

confidence: 59%

A Morbid Obese Japanese Woman with a Body Mass Index of 83.2 kg/m<sup>2</sup>: Before and after Sleeve Gastrectomy

et al. 2012

View full text Add to dashboard Cite

A 34-year-old Japanese woman presented at our institution weighing 182.7 kg, 148.2 cm tall, and with a body mass index of 83.2 kg/m 2 . She had been overweight since childhood, but no abnormality was found to explain her obesity. Treatments, including mazindol, bofu-tsusho-san, dietary restriction, and BioEnterics Intragastric Balloon, did not result in improvement of her obesity. Finally, we performed sleeve gastrectomy, and she has maintained her weight within 130-140 kg without rebounding for 2 and a half years. We followed the clinical changes before and after the operation. This case provides potentially interesting information regarding operative treatment for morbid obesity in Japanese.

show abstract

“…Long-term clinical evaluations such as the DPP 18 or the FDPS 8 typically demonstrate an initial reduction in body weight during the early months of therapy, followed by a tendency for the effect to reverse during continued treatment. Furthermore, metformin has been shown to reduce food intake in studies of up to 15 days, 27,28 and the gastrointestinal side effects of metformin tend to appear early in therapy and may exert undue influence on the results of short-term studies. 29 This is not a formal meta-analysis.…”

Section: Data Sourcesmentioning

confidence: 99%

Metformin and body weight

2007

View full text Add to dashboard Cite

Most patients with type 2 diabetes are overweight or obese, overweight or obesity increases the risk of developing type 2 diabetes and obesity per se is strongly associated with multiple cardiometabolic risk factors. However, many antidiabetic treatments increase body weight. The oral antidiabetic agent, metformin, has been evaluated in hundreds of clinical studies in diverse patient populations during approximately five decades of clinical use. This review summarizes the effects of metformin on body weight, with special reference to studies of longer duration (X6 months) as both diabetes and obesity are long-term conditions. Approximately half of studies in drug-naive type 2 diabetic patients demonstrated significant weight loss with metformin compared with baseline or comparator drugs, although pooled analyses have suggested no significant effect versus placebo. Similarly, metformin has been shown to induce weight loss in obese nondiabetic populations, although studies of long duration in this population are scarce. Metformin does appear to mitigate the adverse effects of insulin on body weight. The weight-neutral or weight-sparing effects of metformin constitute a therapeutic advantage in diabetes management where other first-line oral antidiabetic treatments often promote clinically significant weight gain.

show abstract

Effect of metformin on food intake in obese subjects

Abstract: Our study suggests that metformin administration is useful to inhibit FI and to lower BW and BF in obese non-diabetic patients.

Cited by 125 publications

References 23 publications

Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

A Morbid Obese Japanese Woman with a Body Mass Index of 83.2 kg/m<sup>2</sup>: Before and after Sleeve Gastrectomy

Metformin and body weight

Contact Info

Product

Resources

About